Abstract | PURPOSE: METHODS: Sixteen patients with HES/CEL were enrolled in the phase 2 nilotinib registration trial (NCT00109707) and treated with nilotinib 400 mg twice daily. The median duration of treatment was 95 days (range 3-1,079). RESULTS: Twelve patients had HES: 1 achieved a complete hematologic response (CHR), 3 achieved stable disease, 3 had progressive disease, and 5 were not evaluable for response. Four patients had CEL: 2 with the F/P fusion and 2 with PDGFRα-activating mutations. Both patients with an F/P fusion achieved a CHR; 1 also achieved a complete molecular response (CMR). Of the 2 patients with PDGFRα-activating mutations, 1 had stable disease and the other achieved CMR. At 24 months, overall survival in the HES group was 75.0 % (95 % CI 50.5-100.0) and no patients in the CEL group died. Median survival was not yet reached after a median follow-up of 32 months. The most common grade 3/4 hematologic laboratory abnormalities were lymphocytopenia (31.3 %) and neutropenia (25.0 %). The most common drug-related nonhematologic grade 3/4 adverse event was pruritus, which occurred in 2 patients (12.5 %). CONCLUSIONS:
Nilotinib 400 mg twice daily was effective in some patients with HES/CEL regardless of F/P mutation status, and the safety profile was consistent with other nilotinib studies.
|
Authors | Andreas Hochhaus, Philipp D le Coutre, Hagop M Kantarjian, Michele Baccarani, Philipp Erben, Andreas Reiter, Tracey McCulloch, Xiaolin Fan, Steven Novick, Francis J Giles |
Journal | Journal of cancer research and clinical oncology
(J Cancer Res Clin Oncol)
Vol. 139
Issue 12
Pg. 1985-93
(Dec 2013)
ISSN: 1432-1335 [Electronic] Germany |
PMID | 24057647
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Protein Kinase Inhibitors
- Pyrimidines
- nilotinib
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Chronic Disease
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Hypereosinophilic Syndrome
(drug therapy, mortality, pathology)
- Male
- Middle Aged
- Protein Kinase Inhibitors
(administration & dosage)
- Pyrimidines
(administration & dosage)
- Treatment Outcome
|